5.86
-0.01 (-0.26%)
| Penutupan Terdahulu | 5.88 |
| Buka | 5.88 |
| Jumlah Dagangan | 2,287,917 |
| Purata Dagangan (3B) | 3,062,567 |
| Modal Pasaran | 1,683,935,616 |
| Harga / Jualan (P/S) | 302.09 |
| Harga / Buku (P/B) | 8.89 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Aug 2026 |
| Margin Operasi (TTM) | -930.54% |
| EPS Cair (TTM) | -0.340 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -32.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 111.93% |
| Nisbah Semasa (MRQ) | 5.35 |
| Aliran Tunai Operasi (OCF TTM) | -83.45 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -52.28 M |
| Pulangan Atas Aset (ROA TTM) | -35.91% |
| Pulangan Atas Ekuiti (ROE TTM) | -159.34% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Taysha Gene Therapies, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.00 |
|
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 12.11% |
| % Dimiliki oleh Institusi | 67.23% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |